Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
Bio-IT World September 9, 2002 Malorye Branca	In Like a LION ... The Once and Future King? LION Biosciences CEO Friedrich von Bohlen talks about his undaunted support for his vision for the company.
Bio-IT World July 11, 2002 Malorye Branca	Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed.
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Bio-IT World December 10, 2002 Malorye Branca	The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D.
Bio-IT World March 10, 2003 Mark D. Uehling	Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together.
Bio-IT World March 8, 2005 John Russell	Debating Business Models for Bioinformatics Companies Nailing down a single formula for successfully selling bioinformatics products or services has proven elusive. Harvard Business School tackles informatics' basic question: Where's the money?
Knowledge@Wharton	A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies...
Bio-IT World January 21, 2005	Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics.
Bio-IT World August 13, 2002 Malorye Branca	The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed?
Bio-IT World September 2006 Mike May	Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.
Bio-IT World November 14, 2003 Malorye Branca	Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines.
Bio-IT World November 2005	Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development.
Industrial Physicist Jennifer Ouellette	Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems
Bio-IT World February 2006 Nancy Weil	The Evolving Boon of Bioinformatics As the heady days of cracking the human genome gave way to day-to-day work on a plethora of new drug targets, many bioinformaticians have reached a career crossroads, going to work for major consultancies, starting their own such small firms, or switching to academia.
Bio-IT World August 13, 2003 Branca et al.	Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising.
Bio-IT World November 12, 2002 Michael Goldman	A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
Bio-IT World October 14, 2004 Salvatore Salamone	Riding the New Wave New offerings from Accelrys, LION bioscience, MDL, Synthematix, and Tripos may be the crest of a new wave of software designed to meet increasing demand to incorporate chemoinformatics into the drug discovery process.
Bio-IT World September 11, 2003 Richard D. Gill	The Challenge for in silico Drug Companies Is this the end of the in silico drug discovery and development market?
Bio-IT World January 13, 2003 John Dodge	Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Bio-IT World June 12, 2002 Beth Schachter	Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back up that bet?
Bio-IT World October 9, 2002 Kevin Davies	Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business.
Bio-IT World February 18, 2004	Correspondence One of the Top Three Worst Ideas... Bioinformatics: Reasons to Believe...
Bio-IT World March 2006 John Russell	Genzyme's Guerilla Informatics Whether by wisdom or necessity, Genzyme didn't fall prey to industry infatuation with bioinformatics tools.
Bio-IT World July 14, 2004 Malorye A. Branca	The Pathways Promise By using the right tools, even a modest genomic data set can generate a good view into a particular biological pathway. Now, a range of new technologies is arising from academia as well as the commercial sector to meet this need.
Bio-IT World October 9, 2002 Malorye Branca	The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response.
Bio-IT World March 10, 2003 Michael Greeley	Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand?
Bio-IT World April 15, 2003 Malorye Branca	Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
Bio-IT World September 2005 Kevin Davies	Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials.
Bio-IT World October 2005 John Russell	Compugen Transforms Its Business Many informatics pioneers discovered the hard way that selling software licenses and fee-for-services can't always pay the bills. Tel Aviv-based Compugen, is working to reinvent itself as a drug discovery and development player.
Bio-IT World August 18, 2004 Judy Hanover	Do ASPs Work for Life Science? Clinical trial data management is a natural fit for the application service providers (ASP) model. But ASPs have not been successful with bioinformatics tools.
Bio-IT World September 2006 John A. Wass	Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem.
Knowledge@Wharton	From Skin Creams to Life Insurance to Medical Care, Biosciences Are the New Frontier of Business Opportunity Research in the biological sciences holds the potential for breakthroughs that could transform the world. But scientific advances also can be baffling and more than a little intimidating, especially for business people...
Bio-IT World June 12, 2002 Morris R. Levitt	A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity.
Bio-IT World July 11, 2002 Mike Fitzgerald	Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field.
Bio-IT World November 19, 2004 Malorye A. Branca	Engines of Discovery It's what every biotech startup promises but few deliver, a turbo-charged discovery engine. Every now and then, however, a new company with fresh ideas starts hitting home runs.
Bio-IT World March 2006	Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc.
Bio-IT World July 11, 2002 Stephen T.C. Wong	Neuro-IT Needs Integrated Infrastructure There are two major motivations for merging enterprise solutions into clinical neuroscience. The first is the need to scale up the capacity for data management. The second is the economic benefits of data sharing, software reuse, and infrastructure build-out while reducing costs.
Bio-IT World September 9, 2002	Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?...
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.
Salon.com February 26, 2002 Annalee Newitz	Genome liberation The information that details who we are is too important to be privately owned...
Bio-IT World July 11, 2002 Judith N. Mottl	Learning to Love Linux Hungry for computing power, life science companies are turning toward Linux clusters as the preferred high performance solution.
Bio-IT World November 19, 2004 Kevin Davies	The Book on Bioinformatics Research director David Mount talks about his new book "Bioinformatics: Sequence and Genome Analysis," sequence analysis, and teaching bioinformatics
Bio-IT World November 2006 Kevin Davies	Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.
Bio-IT World Dec 2006/Jan 2007 Kevin Davies	The NextBio Thing in Bioinformatics NextBio, which this fall officially introduced its platform after a year of beta testing by a handful of select organizations, aims to provide high-throughput information to researchers without them having to learn anything.
Bio-IT World February 2007	Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc.
Bio-IT World May 9, 2003 Vivien Marx	The Sharper Image See it, capture it, mine it, find it. The budding field of image informatics is empowering biomedical research.
Bio-IT World June 2006 Kevin Davies	The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine.